KRYS Stock Risk & Deep Value Analysis
Krystal Biotech Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About KRYS Stock
We analyzed Krystal Biotech Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran KRYS through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
How Risky Is KRYS Stock?
Overall Risk
Aggressive
Financial Risk
Low
Market Risk
Medium
Competitive Risk
Medium
Execution Risk
Medium
Regulatory Risk
High
What Are the Red Flags for KRYS?
- ⚠
AATD pivotal clinical trial failure or suboptimal data
- ⚠
Vyjuvek commercial underperformance or slower-than-expected ramp-up
- ⚠
Regulatory delays or unexpected safety concerns for pipeline assets
- ⚠
Emergence of competitive gene therapies with superior efficacy or delivery
Unlock KRYS Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does Krystal Biotech Inc (KRYS) Do?
Market Cap
$5.35B
Sector
Healthcare
Industry
Biotechnology
Employees
275
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Visit Krystal Biotech Inc WebsiteIs KRYS Stock Undervalued?
Unlock the full AI analysis for KRYS
Get the complete DVR score, risk analysis, and more
Is KRYS Financially Healthy?
P/E Ratio
37.58
Does KRYS Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
3 Identified
Krystal Biotech's moat is primarily driven by its proprietary STAR-D platform and robust intellectual property, along with the high regulatory barriers and significant development costs in gene therapy. The in-house manufacturing provides a cost and supply chain advantage. As more products are commercialized from the platform, switching costs for physicians and patients in rare disease areas will increase, solidifying its position. However, rapid advancements in gene editing or alternative therapeutic modalities could present long-term challenges.
Moat Erosion Risks
- •Patent challenges or expiry for key assets
- •Emergence of superior or more convenient gene editing technologies
- •Manufacturing scalability issues or cost increases for new products
KRYS Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive KRYS Stock Higher?
Near-Term (0-6 months)
- •Q4 2025 Earnings Report (Estimated Feb 28, 2026)
- •AATD pivotal trial interim data or full readout (Expected Q2 2026)
- •Vyjuvek EU approval decision (Expected H2 2026)
Medium-Term (6-18 months)
- •AATD Biologics License Application (BLA) / Marketing Authorization Application (MAA) submission (Expected H2 2026)
- •Progression of additional STAR-D platform candidates into clinical trials (Late 2026 / Early 2027)
- •Potential label expansion for Vyjuvek into related indications (2027)
Long-Term (18+ months)
- •Multiple STAR-D platform assets achieving commercialization success
- •Establishment as a global leader in gene therapy for rare genetic diseases
- •Potential platform licensing opportunities with larger pharmaceutical partners
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for KRYS?
- ✓
Acceleration in Vyjuvek revenue growth and patient adherence rates
- ✓
Positive pivotal clinical trial data for the AATD program
- ✓
Successful progression of additional STAR-D pipeline candidates into the clinic
- ✓
Achievement of cash flow positivity
Bull Case Analysis
See what could go right with Premium
Compare KRYS to Similar Stocks
See how Krystal Biotech Inc stacks up against related companies in our head-to-head analysis.
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for KRYS (Krystal Biotech Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
